|
Base line characteristic
|
Controlled NCD N(%)
|
p value
|
|---|
|
Age category
|
|
< 40
|
16 (19.8)
| |
|
40–50
|
38 (46.9)
| |
|
> 50
|
27 (33.3)
|
0.974
|
|
Sex
|
|
Male
|
25 (30.9)
| |
|
Female
|
56 (69.1)
|
0.072
|
|
NCD
|
|
DM only
|
2 (2.5)
| |
|
HTN only
|
74 (91.4)
| |
|
HTN and DM
|
5 (6.2)
|
0.430
|
|
BMI
|
|
< 18.5
|
0 (0)
| |
|
18.5–< 25
|
9 (20.9)
| |
|
25–< 30
|
9 (20.9
|
0.654
|
|
> 30
|
25 (58.1)
| |
|
WHO stage
|
|
0
|
25 (30.9)
| |
|
1
|
21 (25.9)
| |
|
2
|
26 (32.1)
| |
|
3
|
3 (3.7)
| |
|
4
|
6 (7.4)
|
0.012
|
|
CD4 count category
|
|
< 350
|
35 (61.4)
| |
|
> 350
|
22 (38.6)
|
0.404
|
|
Duration on ART
|
|
0–5
|
59 (72.8)
| |
|
6–10
|
22 (27.2)
| |
|
> 10
|
0 (0)
|
0.486
|
|
Duration with HIV
|
|
0–5
|
37 (58.7)
| |
|
6–10
|
18 (28.6)
| |
|
> 10
|
8 (12.7)
|
0.537
|
|
Duration with NCD
|
|
0–5
|
36 (72)
| |
|
6–10
|
13 (26.0)
| |
|
> 10
|
1 (2.0)
|
0.004
|
|
Good adherence
|
|
No
|
4 (4.94)
| |
|
Yes
|
77 (95.1)
|
0.204
|
|
Facility
|
|
A
|
33 (40.7)
| |
|
B
|
48 (59.6)
|
0.004
|
- Bold p values indicated statitistical significance
